诺和诺德的胰高血糖素样肽-1受体激动剂Wegovy于2021年首次获得针对成人肥胖症的批准，并于2022年将其标签扩展至包括12岁及以上的青少年。近日，该药物标签再次扩展，至用于降低心血管疾病风险，这使其成为第一个在药物标签上做出此类声明的减肥药物。美国食品药品监督管理局(FDA)批准Wegovy(semaglutide，司美格鲁肽)的...
参考来源:‘Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity’,新闻稿。Novo Nordisk;2024年3月9日发布。 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。
The FDA recently approved semaglutide (Wegovy) for preventing serious heart conditions in some people, but questions remain about how it works.When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The...
Wegovy's approval for heart disease The FDA originally approved Wegovy in June 2021 as an aid in weight loss for adults with overweight or obesity and at least one other weight-related condition, such as type 2 diabetes, high cholesterol, or high blood pressure. In March, 2024, the FDA ...
参考来源:‘Wegovy receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity’,新闻稿。Novo Nordisk。 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。
参考来源:‘Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity’,新闻稿。Novo Nordisk;2024年3月9日发布。 注:本文旨在介绍医药健康研究,不作任何用药依据,具体用药指引,请咨询主治医师。...
Wegovy(semaglutide) is a weight loss medicine. The FDA first approved Wegovy in 2021 to help people who are overweight or haveobesitylose weight and keep it off. In 2024, Wegovy was also approved to help lower the risk of death due to heart disease, heart attack, and stroke in adults wi...
Wegovy to Be Covered by US Medicare for Heart Disease Patients More Reuters FILE PHOTO: Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams/File Photo By Ahmed Aboulenein and Patrick Wingrove WASHINGTON (Reuters)...
Such conditions include type 2 diabetes, prediabetes, high blood pressure, dyslipidaemia (unbalanced or unhealthy cholesterol levels), obstructive sleep apnoea and heart disease.At the moment, there is a two-year waiting list for Wegovy on the NHS - and last year, research by Sky News showed ...
Medicare Part D prescription plans will start covering the weight loss drug Wegovy when patients also have documented heart disease, according to the U.S. Centers for Medicare and Medicaid Services (CMS).The new policy was announced after the U.S. Food and Drug Administration (FDA) announced ...